Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Arcutis Biotherapeutics, Inc. - Common stock
(NQ:
ARQT
)
23.24
-1.03 (-4.24%)
Streaming Delayed Price
Updated: 2:47 PM EDT, Sep 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcutis Biotherapeutics, Inc. - Common stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Arcutis Announces FDA Acceptance of New Drug Application for Roflumilast Foam 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
April 18, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces New Coverage for ZORYVE® (Roflumilast) Cream 0.3% with National and Regional Health Plan Formularies, Bringing Total Commercial Covered Lives to Over 110 Million
April 05, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Where Arcutis Biotherapeutics Stands With Analysts
↗
March 29, 2023
Via
Benzinga
Arcutis Biotherapeutics's Earnings Outlook
↗
February 27, 2023
Via
Benzinga
Arcutis Shares Gain On Positive Phase 3 Data On Roflumilast Foam In Scalp, Body Psoriasis
↗
September 26, 2022
Via
Benzinga
Atopic Dermatitis Player Arcutis Scoops Up DucentisBioTherapeutics
↗
September 08, 2022
Via
Benzinga
Arcutis Presents Late-Breaking Data from the INTEGUMENT Phase 3 Trials in Atopic Dermatitis at American Academy of Dermatology Annual Meeting
March 18, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Present New Topical Roflumilast Data Including Late Breaking Atopic Dermatitis Pivotal Trial Data During the American Academy of Dermatology (AAD) Annual Meeting
March 09, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 28, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Submits Topical Roflumilast Foam 0.3% New Drug Application to the FDA for the Treatment of Seborrheic Dermatitis in Adults and Adolescents
February 21, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference
February 08, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis' Flagship Psoriasis Treatment Shows Sustained Efficacy, Clearance For Median Of 10 Months
↗
January 17, 2023
Via
Benzinga
Arcutis Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream in Adults with Chronic Plaque Psoriasis
January 14, 2023
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age
December 19, 2022
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older
December 12, 2022
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255
December 05, 2022
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Study Showing Significant Improvements in Itch and Itch-Related Sleep Loss with Roflumilast Cream in Adults with Plaque Psoriasis Published in American Journal of Clinical Dermatology
November 28, 2022
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Biotherapeutics Publishes First Environmental, Social, and Governance (ESG) Report
November 21, 2022
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States
November 17, 2022
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
CORRECTION -- Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
November 15, 2022
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Arcutis Biotherapeutics Stock Surges After Successful Atopic Dermatitis Trial
↗
November 15, 2022
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) announced topline results from its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15% for mild to moderate atopic dermatitis.
Via
Benzinga
Arcutis Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream in Atopic Dermatitis in Adults and Children Aged Six Years and Older
November 15, 2022
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
Why Emergent Bio Is Leading A Biotech Bloodbath — With Xenon Pharma Trailing
↗
November 09, 2022
Biotech stocks were hammered Wednesday, including several that had good news.
Via
Investor's Business Daily
Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update
November 08, 2022
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
↗
October 21, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis
October 21, 2022
From
Arcutis Biotherapeutics, Inc.
Via
GlobeNewswire
What 4 Analyst Ratings Have To Say About Arcutis Biotherapeutics
↗
September 22, 2022
Over the past 3 months, 4 analysts have published their opinion on Arcutis Biotherapeutics (NASDAQ:ARQT) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Important Biotech Catalysts For September 9, 2022 - End Of The Day Summary
↗
September 09, 2022
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
↗
September 07, 2022
Upgrades
Via
Benzinga
Why PolyPid Dipped Over 73%; Here Are 60 Biggest Movers From Friday
↗
September 06, 2022
Gainers Venus Concept Inc. (NASDAQ: VERO) jumped 54.9% to settle at $0.5419 on Friday. The company, last month, posted downbeat quarterly results.
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
